Literature DB >> 24305447

The muscular dystrophies.

Matthew P Wicklund.   

Abstract

PURPOSE OF REVIEW: With transition to the genetic era, the number of muscular dystrophies has grown significantly, but so too has our understanding of their pathogenic underpinnings. Clinical features associated with each muscular dystrophy still guide us to the diagnosis. However, improved diagnostic abilities refine and expand phenotypic and genotypic correlates. This article discusses the epidemiology, clinical features, and diagnosis of these disorders. RECENT
FINDINGS: Some important recent advancements include (1) a much greater understanding of the pathogenetic pathways underlying facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1; (2) the publication of diagnostic and treatment guidelines for Duchenne muscular dystrophy; and (3) further clarification of the many genetic muscle disorders presenting a limb-girdle pattern of weakness.
SUMMARY: Muscular dystrophies are genetic, progressive, degenerative disorders with the primary symptom of muscle weakness. Duchenne, Becker, facioscapulohumeral, and myotonic muscular dystrophies are most prevalent and tend to have distinctive features helpful in diagnosis. The limb-girdle, Emery-Dreifuss, and oculopharyngeal muscular dystrophies are less common but often may also be diagnosed on the basis of phenotype. Researchers hope to help patients with future discoveries effective in slowing or halting disease progression, reversing or preventing underlying mechanisms, and repairing previously damaged muscle.

Entities:  

Mesh:

Year:  2013        PMID: 24305447     DOI: 10.1212/01.CON.0000440659.41675.8b

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  11 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Label-Free, High-Throughput Purification of Satellite Cells Using Microfluidic Inertial Separation.

Authors:  Brian C Syverud; Eric Lin; Sunitha Nagrath; Lisa M Larkin
Journal:  Tissue Eng Part C Methods       Date:  2017-11-06       Impact factor: 3.056

3.  Normal muscle structure, growth, development, and regeneration.

Authors:  Wladimir Bocca Vieira de Rezende Pinto; Paulo Victor Sgobbi de Souza; Acary Souza Bulle Oliveira
Journal:  Curr Rev Musculoskelet Med       Date:  2015-06

4.  Transplantation of Human Adipose Mesenchymal Stem Cells in Non-Immunosuppressed GRMD Dogs is a Safe Procedure.

Authors:  M V Pelatti; J P A Gomes; N M S Vieira; E Cangussu; V Landini; T Andrade; M Sartori; L Petrus; Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

5.  The genetic basis of undiagnosed muscular dystrophies and myopathies: Results from 504 patients.

Authors:  Marco Savarese; Giuseppina Di Fruscio; Annalaura Torella; Chiara Fiorillo; Francesca Magri; Marina Fanin; Lucia Ruggiero; Giulia Ricci; Guja Astrea; Luigia Passamano; Alessandra Ruggieri; Dario Ronchi; Giorgio Tasca; Adele D'Amico; Sandra Janssens; Olimpia Farina; Margherita Mutarelli; Veer Singh Marwah; Arcomaria Garofalo; Teresa Giugliano; Simone Sampaolo; Francesca Del Vecchio Blanco; Gaia Esposito; Giulio Piluso; Paola D'Ambrosio; Roberta Petillo; Olimpia Musumeci; Carmelo Rodolico; Sonia Messina; Anni Evilä; Peter Hackman; Massimiliano Filosto; Giuseppe Di Iorio; Gabriele Siciliano; Marina Mora; Lorenzo Maggi; Carlo Minetti; Sabrina Sacconi; Lucio Santoro; Kathleen Claes; Liliana Vercelli; Tiziana Mongini; Enzo Ricci; Francesca Gualandi; Rossella Tupler; Jan De Bleecker; Bjarne Udd; Antonio Toscano; Maurizio Moggio; Elena Pegoraro; Enrico Bertini; Eugenio Mercuri; Corrado Angelini; Filippo Maria Santorelli; Luisa Politano; Claudio Bruno; Giacomo Pietro Comi; Vincenzo Nigro
Journal:  Neurology       Date:  2016-06-08       Impact factor: 9.910

Review 6.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

7.  How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration.

Authors:  Pat Furlong; John F P Bridges; Lawrence Charnas; Justin R Fallon; Ryan Fischer; Kevin M Flanigan; Timothy R Franson; Neera Gulati; Craig McDonald; Holly Peay; H Lee Sweeney
Journal:  Orphanet J Rare Dis       Date:  2015-06-24       Impact factor: 4.123

8.  Mechanisms of Myofascial Pain.

Authors:  M Saleet Jafri
Journal:  Int Sch Res Notices       Date:  2014

9.  Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro.

Authors:  Anchel González-Barriga; Bram Nillessen; Julia Kranzen; Ingeborg D G van Kessel; Huib J E Croes; Begoña Aguilera; Peter C de Visser; Nicole A Datson; Susan A M Mulders; Judith C T van Deutekom; Bé Wieringa; Derick G Wansink
Journal:  Nucleic Acid Ther       Date:  2017-04-04       Impact factor: 5.486

10.  Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol.

Authors:  Yoshiki Ohnuki; Daisuke Umeki; Yasumasa Mototani; Kouichi Shiozawa; Megumi Nariyama; Aiko Ito; Naoya Kawamura; Yuka Yagisawa; Huiling Jin; Wenqian Cai; Kenji Suita; Yasutake Saeki; Takayuki Fujita; Yoshihiro Ishikawa; Satoshi Okumura
Journal:  Physiol Rep       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.